Early addition of rituximab in the management of myositis associated with systemic lupus erythematosus
Targeting B-cell in systemic lupus erythematosus (SLE) seems to be a promising approach. Although rituximab failed to show efficacy in refractory SLE in clinical trial setting, real-world experience still shows some efficacy in certain situations. A 20-year-old woman was diagnosed with SLE with coex...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
SpringerOpen,
2019-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|